Ask about this productRelated genes to: TET2 antibody
- Gene:
- TET2 NIH gene
- Name:
- tet methylcytosine dioxygenase 2
- Previous symbol:
- KIAA1546
- Synonyms:
- FLJ20032
- Chromosome:
- 4q24
- Locus Type:
- gene with protein product
- Date approved:
- 2006-06-20
- Date modifiied:
- 2019-04-23
Related products to: TET2 antibody
Related articles to: TET2 antibody
- Nodal T-follicular helper cell lymphomas (nTFHL) are aggressive peripheral T-cell lymphomas with unique clinical-biological features. B-cell and/or plasma cell proliferations (B/PCP) are frequently reported in nTFHL, yet their histological spectrum remains incompletely defined. This study aims to delineate the clinical, pathological and molecular features of a retrospective series of nTFHL-associated B/PCP, with particular emphasis on recurrent disease patterns. To this aim, we retrospectively analyzed 39 nTFHL with 45 synchronous and/or metachronous B/PCP, collected from five Italian referral centers for hematological disorders. Multiple B/PCP were documented in 5/39 (12.8%) patients. All diagnoses were established according to the 2022 WHO/ICC criteria, using the nomenclature proposed by the 2023 SH/EA4HP Workshop on T-cell lymphomas. Clinical and pathological data were collected, and recurrent histological patterns were categorized. RHOA, TET2, DNMT3A, and IDH2 mutations were tested in 16 cases. The cohort included 20 males and 19 females (median age: 73.3 years). B/PCP clustered into six diagnostic categories: (i) diffuse large B-cell lymphoma (DLBCL)-like proliferations associated with nTFHL (19/45 [42.2%]), (ii) nodular large B-cell proliferations associated with nTFHL (5/45 [11.1%]), (iii) secondary DLBCL without co-localization of nTFHL (3/45 [6.7%]); (iv) EBV-positive polymorphic B-cell proliferations (10/45 [22.2%]), (v) monotypic plasma cell proliferations (5/45 [11.1%]), and (vi) small B-cell lymphoma-like proliferations with plasma cell differentiation (3/45 [6.7%]). TET2 mutations were detected in 10/16 (62.5%) cases with high allelic burden, whereas DNMT3A and IDH2 mutations were rare. The RHOA mutation was detected in 3 cases, most likely representing contamination by minor nTFHL clones. In conclusion, TFHL-associated B/PCP are a heterogeneous group of lymphoproliferative and plasma cell disorders, displaying recurrent histological patterns and frequent clonal hematopoiesis-associated mutations. Further studies on larger cohorts of patients are warranted to elucidate their biological and clinical implications. - Source: PubMed
Publication date: 2026/04/30
Pizzi MarcoLorenzi LuisaDe Crescenzo AndreaCroci Giorgio AlbertoScarmozzino FedericoSantoro LuisaMandelli Giulio EugenioFusi MatteoCocchi Marco AngeloBalzarini PieraCaniato GiorgiaBellan ElenaFilippi BarbaraScapinello GretaPiazza FrancescoVianello FabrizioPagani ChiaraLa Marra FrancescoFamengo BarbaraBonaldi LauraFassan MatteoRighi SimonaDei Tos Angelo PaoloSabattini Elena - Clonal hematopoiesis of indeterminate potential (CHIP) is an age-associated condition whose population-level characteristics and clinical concordance in Japan remain incompletely defined. We analyzed whole-genome sequencing data from 49,982 participants in the Tohoku Medical Megabank (TMM) cohort to characterize the prevalence, mutational spectrum, age dependency, and clinical relevance of CHIP. CHIP mutations were detected in 1234 individuals (2.5%), comprising 1413 variants across 1015 loci. DNMT3A and TET2 were the most frequently mutated genes, whereas ASXL1 and PPM1D mutations were less prevalent than reported in Western cohorts. Four recurrent CHIP candidate loci (ZNF318, SMC3, CBL, and GNAS) were identified, most of which were predicted to be oncogenic. Comparison with TOPMed and UK Biobank datasets demonstrated overall concordance in variant prevalence, with differences observed for selected driver mutations. dN/dS analysis indicated positive selection in the majority of CHIP-associated genes. Concordance with clonal hematopoiesis (CH) mutations detected in cancer patients was evaluated using data from the MONSTAR-SCREEN-2 study with paired leukocyte sequencing. When focusing on genes in which CHIP mutations have been reported, 66% were confirmed as CH, yielding a positive predictive value of 66% and a negative predictive value of 76%. CHIP prevalence increased significantly with age, exceeding 5% in individuals aged ≥ 70 years, with an estimated 3.4% increase per additional year of age. Higher variant allele frequency mutations showed a slightly stronger age association. These findings define the landscape of CHIP in the Japanese population and clarify its relationship to CH detected by cancer-focused liquid biopsy assays. - Source: PubMed
Publication date: 2026/04/29
Chi SungGiMotoike Ikuko NFujisawa TakaoYamaguchi-Kabata YumiNobukuni TakahiroKinoshita KengoNakamura YoshiakiBando HideakiYoshino TakayukiOhneda KinukoTsuchihara KatsuyaMinami YosukeYamashita Riu - The geographic diversity of molecular genetic abnormalities in AML can help understand the genetic and environmental factors involved in the development of leukemia. In addition, high-risk groups can be recognized by identifying common mutations in AML patients, and appropriate treatment based on the type of mutation can be adopted. This systematic study and meta-analysis analyzed the common mutations in AML patients in Iran. - Source: PubMed
Publication date: 2026/01/11
Khaksari Mohammad NavidMeghdadi MohammadrezaRostami MehrdadKhoshnegah ZahraBoroumand-Noughabi SamanehBazi AliKhiabani AlirezaKeramati Mohammad Reza - TET2 mutations are frequent in TFH-derived lymphomas, but how epigenetic disruption initiates malignant T cell transformation is unclear. We generated Cd4cre;Tet2FL/FL mice, which developed aggressive T cell lymphoma (m-TCL) with a TFH cell-like immunophenotype. Genome-wide transcriptomics and epigenetic profiling of Tet2-/- CD4+ T cells prior to lymphoma development showed hyperactive TCR, PI3K signaling, and dysregulated TH differentiation program, with proliferation promoting signal transduction at the lymphoma stage. Tet2 loss promoted hyperplasticity under in vitro conditions but favored conditional TFH differentiation. Reduced 5-hmC levels at regulatory genomic elements, resulted in transcriptional rewiring of TFH-associated genes, promoting ICOS(L)-mediated PI3K signaling. TET2-KO human CD4+ T cells showed conserved epigenetic changes with increased proliferation, decreased exhaustion, increased memory marker expression, and clonal expansion with restricted TCR repertoire under in vitro conditions. scRNA-seq revealed a persistent proliferative cluster characterized by elevated stem-like transcriptional features compared with WT counterparts. Tet2-/- m-TCLs allografted into NSG mice showed a significant response to epigenetic (5-azacytidine) and PI3K inhibitors (duvelisib) alone or in combination. - Source: PubMed
Publication date: 2026/04/28
Heavican-Foral Tayla BLi YupingLone WaseemBouska AlyssaZhang JibinYang RuimengLiu XuxiangShah Ab RaufMir Abdul RoufRohr JosephJochum DylanKumar AnuragChawla Ravneet SinghAmador CatalinaYu JiayuHerek TylerRobinson JacobBi ChengfengSharma SunandiniGilbreath TylerHyde R KatherineMcKeithan Timothy WLio Chan-WangRao AnjanaInghirami GiorgioKhoury JoesphChan Wing CIqbal Javeed - - Source: PubMed
Zhu YixiaoLin LiWei Xiaoxia